Identifying dysfunctional cell types and circuits in animal models for psychiatric disorders with calcium imaging
- PMID: 39122815
- PMCID: PMC11525937
- DOI: 10.1038/s41386-024-01942-y
Identifying dysfunctional cell types and circuits in animal models for psychiatric disorders with calcium imaging
Erratum in
-
Correction: Identifying dysfunctional cell types and circuits in animal models for psychiatric disorders with calcium imaging.Neuropsychopharmacology. 2024 Nov;50(1):305. doi: 10.1038/s41386-024-01982-4. Neuropsychopharmacology. 2024. PMID: 39251775 Free PMC article. No abstract available.
-
Correction: Neuropsychopharmacology Volume 50 Issue 1.Neuropsychopharmacology. 2025 May;50(6):1019-1020. doi: 10.1038/s41386-025-02087-2. Neuropsychopharmacology. 2025. PMID: 40108440 Free PMC article. No abstract available.
Abstract
A central goal of neuroscience is to understand how the brain transforms external stimuli and internal bodily signals into patterns of activity that underlie cognition, emotional states, and behavior. Understanding how these patterns of activity may be disrupted in mental illness is crucial for developing novel therapeutics. It is well appreciated that psychiatric disorders are complex, circuit-based disorders that arise from dysfunctional activity patterns generated in discrete cell types and their connections. Recent advances in large-scale, cell-type specific calcium imaging approaches have shed new light on the cellular, circuit, and network-level dysfunction in animal models for psychiatric disorders. Here, we highlight a series of recent findings over the last ~10 years from in vivo calcium imaging studies that show how aberrant patterns of activity in discrete cell types and circuits may underlie behavioral deficits in animal models for several psychiatric disorders, including depression, anxiety, autism spectrum disorders, and schizophrenia. These advances in calcium imaging in pre-clinical models demonstrate the power of cell-type-specific imaging tools in understanding the underlying dysfunction in cell types, activity patterns, and neural circuits that may contribute to disease and provide new blueprints for developing more targeted therapeutics and treatment strategies.
© 2024. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Conflict of interest statement
The authors declare no competing interests.
References
Publication types
MeSH terms
Substances
Grants and funding
- DSPAN F99/K00 NS130927/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- R01 DC019813/DC/NIDCD NIH HHS/United States
- R01 MH111754/MH/NIMH NIH HHS/United States
- F99 NS130927/NS/NINDS NIH HHS/United States
- R01 MH108623/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
